Related Experiment Videos
Imipenem-cilastatin. A new dimension
Abstract:
Imipenem/cilastatin (Tienam 500; Logos) 1 g, administered intravenously every 8 hours, was evaluated in an open clinical trial in 35 patients with severe nosocomial pneumonia. In 84.4% of cases there was a favourable clinical response; microbiological success was achieved in 63.3% and partial success in 20% of patients. The majority of Gram-negative and Gram positive organisms were sensitive to imipenem, including those resistant to the aminoglycosides. Although colonisation was frequent, superinfection was uncommon. Imipenem was well tolerated in these critically ill patients, many of whom had renal and other organ failure. The wide spectrum of antimicrobial activity and minimal side-effects made it a useful agent in patients with severe nosocomial pneumonia.
Insights
Imipenem/cilastatin demonstrated high clinical success rates in severe nosocomial pneumonia. This broad-spectrum antibiotic was well-tolerated, even in critically ill patients with organ failure.
Area of Science:
- Infectious Diseases
- Clinical Pharmacology
- Critical Care Medicine
Background:
- Severe nosocomial pneumonia presents significant treatment challenges.
- Identifying effective antimicrobial agents is crucial for patient outcomes.
- Imipenem/cilastatin is a broad-spectrum antibiotic with potential utility in complex infections.
Purpose of the Study:
- To evaluate the efficacy and tolerability of imipenem/cilastatin in patients with severe nosocomial pneumonia.
Main Methods:
- An open clinical trial involving 35 patients with severe nosocomial pneumonia.
- Intravenous administration of imipenem/cilastatin (1 g) every 8 hours.
- Assessment of clinical response, microbiological success, and adverse events.
Main Results:
- A favorable clinical response was observed in 84.4% of patients.
- Microbiological success was achieved in 63.3%, with partial success in 20%.
- Organisms, including aminoglycoside-resistant strains, were largely sensitive to imipenem; superinfections were uncommon.
Conclusions:
- Imipenem/cilastatin is an effective and well-tolerated treatment option for severe nosocomial pneumonia.
- Its broad antimicrobial spectrum is beneficial, particularly in critically ill patients.
- Minimal side-effects were noted, even in patients with renal or organ failure.